Jose-Carlos Gutiérrez-Ramos
Chief Tech/Sci/R&D Officer at DANAHER CORPORATION
Net worth: 4 M $ as of 2024-03-30
Profile
Dr. Jose Carlos Gutiérrez Ramos is an Independent Director at Bicycle Therapeutics Plc, a Chief Science Officer & Senior Vice President at Danaher Corp., a President & Chief Executive Officer at Cogen Immune Medicine, Inc. and a Chief Executive Officer at Excaliard Pharmaceuticals, Inc. He is on the Board of Directors at Bicycle Therapeutics Plc. Dr. Gutiérrez Ramos was previously employed as a Vice President-Drug Discovery by AbbVie, Inc., a President, Chief Executive Officer & Director by Repertoire Immune Medicines, Inc., an Independent Director by Oryzon Genomics SA, an Independent Director by Momenta Pharmaceuticals, Inc., a President & Chief Executive Officer by Synlogic Operating Co., Inc., a President, Chief Executive Officer & Director by Synlogic, Inc., a SVP-Research & Development by Pfizer Inc., a Senior Vice President by Avidia, Inc., a Chief Scientific Officer by Peptimmune, Inc., a Member by Basel Institute for Immunology, a SVP, Head-BioTherapeutics Research & Development by Centers for Therapeutic Innovation, a Chief Scientific Officer by Genetrix, Inc., a Senior Vice President by GlaxoSmithKline AG, an Assistant Professor by Harvard University, a Vice President-Inflammation by Millennium Pharmaceuticals, Inc., and a Professor by National Center for Biotechnology Information. He also served on the board at Evelo Biosciences, Inc. He received his undergraduate degree from Universidad Complutense de Madrid and a doctorate degree from Universidad Autónoma de Madrid.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
DANAHER CORPORATION
0.00% | 2024-02-29 | 12,958 ( 0.00% ) | 3 M $ | 2024-03-30 |
2024-01-01 | 16,750 ( 0.06% ) | 417 075 $ | 2024-03-30 | |
EVELO BIOSCIENCES, INC.
0.00% | 2023-06-07 | 500 ( 0.00% ) | 23 $ | 2024-03-30 |
Jose-Carlos Gutiérrez-Ramos active positions
Companies | Position | Start |
---|---|---|
DANAHER CORPORATION | Chief Tech/Sci/R&D Officer | 2020-12-31 |
BICYCLE THERAPEUTICS PLC | Director/Board Member | 2021-03-16 |
Cogen Immune Medicine, Inc.
Cogen Immune Medicine, Inc. Pharmaceuticals: MajorHealth Technology Cogen Immune Medicine, Inc. develops immune modulation therapeutics which control immune system. Its platform includes therapeutics, vaccines, clinical decision making, and immune health. The company was founded by Noubar B. Afeyan in 2017 and is headquartered in Cambridge, MA. | Chief Executive Officer | 2018-07-31 |
Excaliard Pharmaceuticals, Inc.
Excaliard Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Excaliard Pharmaceuticals, Inc. manufactures, develops therapeutics for the treatment of scarring and fibrotic disorders. The company was founded by John Gordon Foulkes and Nicholas M. Dean in 2006 and is headquartered in New York, NY. | Chief Executive Officer | - |
Former positions of Jose-Carlos Gutiérrez-Ramos
Companies | Position | End |
---|---|---|
EVELO BIOSCIENCES, INC. | Director/Board Member | 2023-11-19 |
ABBVIE INC. | Corporate Officer/Principal | 2020-12-31 |
MOMENTA PHARMACEUTICALS, INC. | Director/Board Member | 2020-09-30 |
EVELO BIOSCIENCES, INC. | Director/Board Member | 2020-02-24 |
ORYZON GENOMICS S.A. | Director/Board Member | 2020-02-20 |
Training of Jose-Carlos Gutiérrez-Ramos
Universidad Complutense de Madrid | Undergraduate Degree |
Universidad Autónoma de Madrid | Doctorate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 8 |
---|---|
DANAHER CORPORATION | Health Technology |
PFIZER, INC. | Health Technology |
ABBVIE INC. | Health Technology |
GSK PLC | Health Technology |
ORYZON GENOMICS S.A. | Health Technology |
BICYCLE THERAPEUTICS PLC | Health Technology |
EVELO BIOSCIENCES, INC. | Health Technology |
SYNLOGIC, INC. | Health Technology |
Private companies | 12 |
---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Momenta Pharmaceuticals, Inc.
Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Avidia, Inc.
Avidia, Inc. Pharmaceuticals: MajorHealth Technology Avidia, Inc. developed pharmaceutical products. The company developed a novel, proprietary class of small therapeutic proteins. The company was headquartered in Mountain View, CA. | Health Technology |
Genetrix, Inc.
Genetrix, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sanofi, Genetrix, Inc. is a genetics testing research company. The private company is based in Scottsdale, AZ. Genetrix was acquired by Genzyme Corp., part of Sanofi from April 08, 2011 on May 06, 1996 for $39.20 million. | Commercial Services |
Peptimmune, Inc.
Peptimmune, Inc. BiotechnologyHealth Technology Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products. | Health Technology |
Excaliard Pharmaceuticals, Inc.
Excaliard Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Excaliard Pharmaceuticals, Inc. manufactures, develops therapeutics for the treatment of scarring and fibrotic disorders. The company was founded by John Gordon Foulkes and Nicholas M. Dean in 2006 and is headquartered in New York, NY. | Health Technology |
GlaxoSmithKline AG
GlaxoSmithKline AG Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline AG is a Swiss company. | Health Technology |
National Center for Biotechnology Information | Government |
Centers for Therapeutic Innovation | |
Synlogic Operating Co., Inc.
Synlogic Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Cogen Immune Medicine, Inc.
Cogen Immune Medicine, Inc. Pharmaceuticals: MajorHealth Technology Cogen Immune Medicine, Inc. develops immune modulation therapeutics which control immune system. Its platform includes therapeutics, vaccines, clinical decision making, and immune health. The company was founded by Noubar B. Afeyan in 2017 and is headquartered in Cambridge, MA. | Health Technology |
Repertoire Immune Medicines, Inc.
Repertoire Immune Medicines, Inc. Miscellaneous Commercial ServicesCommercial Services Repertoire Immune Medicines, Inc. operates as a clinical-stage biotechnology company. It focuses on the immune system to prevent, treat, and cure cancer, autoimmune disorders, and infectious diseases. The company was founded by Noubar Afeyan and is headquartered in Cambridge, MA. | Commercial Services |
- Stock Market
- Insiders
- Jose-Carlos Gutiérrez-Ramos